Advertisement

Topics

Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology

18:34 EST 13 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the publication of previously ...

Other Sources for this Article

Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
or
Russo Partners
David Schull or Amiad Finkelthal, +1 212 845 4200
david.schull@russopartnersllc.com
amiad.finkelthal@russopartnersllc.com

NEXT ARTICLE

More From BioPortfolio on "Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...